A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer

Lung Cancer

Volumn 72, Issue 1, 2011, Pages 64-67

  Rhee, Chin Kook ^a   Lee, Sang Haak ^b   Kim, Ju Sang ^a   Kim, Seung Joon ^a   Kim, Seok Chan ^a   Kim, Young Kyoon ^a   Kang, Hyun Hee ^a   Yoon, Hyoung Kyu ^a   Song, Jeong Sup ^a   Moon, Hwa Sik ^b   Kim, Jin Woo ^c   Kim, Chi Hong ^d   Shim, Byoung Yong ^d   Kim, Hoon Kyo ^d   Sun, Der Sheng ^d   Kim, Kwan Hyoung ^c  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Uijeongbu St Mary's Hospital   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

Belotecan; Chemotherapy; Phase II study; Second line; Single agent; Small cell lung cancer

Indexed keywords

BELOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; TOPOISOMERASE I INHIBITORS; TREATMENT OUTCOME;

EID: 79952192731     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.07.003     Document Type: Article

References (22)

1. Hann C.L., Rudin C.M. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology 2008, 22:1486-1492.
2. Crul M. CKD-602. Chong Kun Dang. Curr Opin Investing Drugs 2003, 4:1455-1459.
3. Lee J.H., Lee J.M., Kim J.K., Ahn S.K., Lee S.J., Kim M.Y., et al. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 1998, 21:581-590.
4. Lee J.H., Lee J.M., Lim K.H., Kim J.K., Ahn S.K., Bang Y.J., et al. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann N Y Acad Sci 2000, 922:324-325.
5. Kim S.J., Kim J.S., Kim S.C., Kim Y.K., Kang J.Y., Yoon H.K., et al. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer. Lung Cancer 2010, 68:446-449.
6. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
7. Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38:143-151.
8. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
9. Eckardt J.R., von Pawel J., Pujol J., Papai Z., Quoix E., Ardizzoni A., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007, 25:2086-2092.
10. Sher T., Dy G.K., Adjei A. Small cell lung cancer. Mayo Clin Proc 2008, 83:355-367.
11. Pallis A.G., Agelidou A., Agelaki S., Varthalitis I., Pavlakou G., Gerogianni A., et al. A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. Lung Cancer 2009, 65:187-191.
12. Rougier P., Bugat R., Douillard J.Y., Culine S., Suc E., Brunet P., et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997, 15:251-260.
13. Cunningham D., Pyrhnen S., James R.D., Punt C.J., Hickish T.F., Heikkila R., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418.
14. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407-1412.
15. Lee D.H., Kim S., Bae K., Hong J., Suh C., Kang Y., et al. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer. Clin Cancer Res 2007, 13:6182-6186.
16. Lee D.H., Kim S.W., Suh C., Lee J.S., Lee J.H., Lee S.J., et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 2008, 19:123-127.
17. Negoro S., Fukuoka M., Niitani H., Suzuki A., Nakabayashi T., Kimura M., et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan To Kagaku Ryoho 1991, 18:1013-1019.
18. Faylona E.A., Loehrer P.J., Ansari R., Sandler A.B., Gonin R., Einhorn L.H. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. J Clin Oncol 1995, 13:1209-1214.
19. Smit E.F., Fokkema E., Biesma B., Groen H.J., Snoek W., Postmus P.E. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998, 77:347-351.
20. Kosmas C., Tsavaris N.B., Malamos N.A., Vadiaka M., Koufos C. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 2001, 19:119-126.
21. Kakolyris S., Mavroudis D., Tsavaris N., Souglakos J., Tsiafaki P., Kalbakis K., et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol 2001, 12:193-197.
22. Sonpavde G., Ansari R., Walker P., Sciortino D.F., Gabrys G.T., Murdock A., et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol 2000, 23:68-70.